{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:40:51Z","timestamp":1794649251698,"version":"4.9.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA244726-01"],"award-info":[{"award-number":["CA244726-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00463774"],"award-info":[{"award-number":["RS-2024-00463774"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00275456"],"award-info":[{"award-number":["RS-2023-00275456"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-002274"],"award-info":[{"award-number":["INV-002274"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"A*STAR International Fellowship"},{"name":"Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea","id":[{"id":"https:\/\/ror.org\/00vxgjw72","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Current SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccines have shown robust induction of neutralizing antibodies and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cell activation; however, CD8\n                    <jats:sup>+<\/jats:sup>\n                    responses are variable, and the duration of immunity and protection against variants are limited. Here we repurpose our DNA origami vaccine nanotechnology DoriVac to target infectious viruses, namely, SARS-CoV-2, HIV and Ebola. The DNA origami nanoparticle, conjugated with infectious-disease-specific heptad repeat 2 peptides, which act as highly conserved antigens, and CpG adjuvant at precise nanoscale spacing, induces neutralizing antibodies, Th1 CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells and CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in naive mice, with significant improvement over a bolus control. Pre-clinical studies using lymph-node-on-a-chip systems validate that DoriVac, when conjugated with antigenic peptides or proteins, induces promising cellular and humoral immune responses in human cells. Moreover, DoriVac bearing full-length SARS-CoV-2 spike protein achieves immune responses comparable to current mRNA vaccine platforms while potentially reducing storage constraints. These results suggest that DoriVac holds potential as a versatile, modular vaccine platform, capable of inducing both humoral and cellular immunities, underscoring its potential future use.\n                  <\/jats:p>","DOI":"10.1038\/s41551-026-01614-w","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:01:39Z","timestamp":1773223299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0566-4976","authenticated-orcid":false,"given":"Yang C.","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2252-6623","authenticated-orcid":false,"given":"Olivia J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-7391","authenticated-orcid":false,"given":"Qiancheng","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-1659","authenticated-orcid":false,"given":"Longlong","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Wen","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie G.","family":"Bernier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawa","family":"Dembele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-1576","authenticated-orcid":false,"given":"Giorgia","family":"Isinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Gilboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Swank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hyun","family":"Seok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Rajwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-217X","authenticated-orcid":false,"given":"Yunhao","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8064-8533","authenticated-orcid":false,"given":"LaTonya D.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb A.","family":"Hellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Wintersinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Graveline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andyna","family":"Vernet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarai","family":"Bardales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3422-3272","authenticated-orcid":false,"given":"Ju Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1272-7074","authenticated-orcid":false,"given":"Ick Chan","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-2205","authenticated-orcid":false,"given":"Girija","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-6520","authenticated-orcid":false,"given":"Donald E.","family":"Ingber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-9267","authenticated-orcid":false,"given":"William M.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"1614_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"1614_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR4","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR5","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech, C. et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 383, 2320\u20132332 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","volume":"592","author":"H Tegally","year":"2021","unstructured":"Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature 592, 438\u2013443 (2021).","journal-title":"Nature"},{"key":"1614_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.3390\/microorganisms9071542","volume":"9","author":"S Cherian","year":"2021","unstructured":"Cherian, S. et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms 9, 1542 (2021).","journal-title":"Microorganisms"},{"key":"1614_CR8","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679\u2013686 (2022).","journal-title":"Nature"},{"key":"1614_CR9","doi-asserted-by":"publisher","first-page":"eabj1750","DOI":"10.1126\/sciimmunol.abj1750","volume":"6","author":"D Geers","year":"2021","unstructured":"Geers, D. et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci. Immunol. 6, eabj1750 (2021).","journal-title":"Sci. Immunol."},{"key":"1614_CR10","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.cell.2021.04.006","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184, 2523 (2021).","journal-title":"Cell"},{"key":"1614_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109415","volume":"36","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Rep. 36, 109415 (2021).","journal-title":"Cell Rep."},{"key":"1614_CR12","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885\u20131898 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR13","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616\u2013622 (2021).","journal-title":"Nature"},{"key":"1614_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","volume":"27","author":"CK Wibmer","year":"2021","unstructured":"Wibmer, C. K. et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27, 622\u2013625 (2021).","journal-title":"Nat. Med."},{"key":"1614_CR15","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1056\/NEJMc2102179","volume":"384","author":"K Wu","year":"2021","unstructured":"Wu, K. et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. N. Engl. J. Med. 384, 1468\u20131470 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aau8408","volume":"4","author":"L Si","year":"2018","unstructured":"Si, L. et al. Triterpenoids manipulate a broad range of virus-host fusion via wrapping the HR2 domain prevalent in viral envelopes. Sci. Adv. 4, eaau8408 (2018).","journal-title":"Sci. Adv."},{"key":"1614_CR17","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1099\/0022-1317-71-12-3075","volume":"71","author":"P Chambers","year":"1990","unstructured":"Chambers, P., Pringle, C. R. & Easton, A. J. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 71, 3075\u20133080 (1990).","journal-title":"J. Gen. Virol."},{"key":"1614_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/nsmb.1456","volume":"15","author":"SC Harrison","year":"2008","unstructured":"Harrison, S. C. Viral membrane fusion. Nat. Struct. Mol. Biol. 15, 690\u2013698 (2008).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1614_CR19","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(00)80205-6","volume":"89","author":"DC Chan","year":"1997","unstructured":"Chan, D. C., Fass, D., Berger, J. M. & Kim, P. S. Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263\u2013273 (1997).","journal-title":"Cell"},{"key":"1614_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1006\/viro.1998.9242","volume":"248","author":"SB Joshi","year":"1998","unstructured":"Joshi, S. B., Dutch, R. E. & Lamb, R. A. A core trimer of the paramyxovirus fusion protein: parallels to influenza virus hemagglutinin and HIV-1 gp41. Virology 248, 20\u201334 (1998).","journal-title":"Virology"},{"key":"1614_CR21","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1073\/pnas.96.6.2662","volume":"96","author":"VN Malashkevich","year":"1999","unstructured":"Malashkevich, V. N. et al. Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc. Natl Acad. Sci. USA 96, 2662\u20132667 (1999).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1614_CR22","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","volume":"53","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity 53, 1315\u20131330.e1319 (2020).","journal-title":"Immunity"},{"key":"1614_CR23","doi-asserted-by":"publisher","first-page":"e50366","DOI":"10.1371\/journal.pone.0050366","volume":"7","author":"HA Elshabrawy","year":"2012","unstructured":"Elshabrawy, H. A., Coughlin, M. M., Baker, S. C. & Prabhakar, B. S. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS ONE 7, e50366 (2012).","journal-title":"PLoS ONE"},{"key":"1614_CR24","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","volume":"181","author":"A Grifoni","year":"2020","unstructured":"Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489\u20131501.e1415 (2020).","journal-title":"Cell"},{"key":"1614_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33209-9","volume":"13","author":"C He","year":"2022","unstructured":"He, C. et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat. Commun. 13, 5459 (2022).","journal-title":"Nat. Commun."},{"key":"1614_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"NC Kyriakidis","year":"2021","unstructured":"Kyriakidis, N. C., L\u00f3pez-Cort\u00e9s, A., Gonz\u00e1lez, E. V., Grimaldos, A. B. & Prado, E. O. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines 6, 28 (2021).","journal-title":"NPJ Vaccines"},{"key":"1614_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41590-020-00808-x","volume":"22","author":"A Nelde","year":"2021","unstructured":"Nelde, A. et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 22, 74\u201385 (2021).","journal-title":"Nat. Immunol."},{"key":"1614_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.cell.2020.11.029","volume":"184","author":"LB Rodda","year":"2021","unstructured":"Rodda, L. B. et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Cell 184, 169\u2013183.e117 (2021).","journal-title":"Cell"},{"key":"1614_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108728","volume":"34","author":"AT Tan","year":"2021","unstructured":"Tan, A. T. et al. Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Rep. 34, 108728 (2021).","journal-title":"Cell Rep."},{"key":"1614_CR30","doi-asserted-by":"publisher","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","volume":"371","author":"JM Dan","year":"2021","unstructured":"Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8?months after infection. Science 371, eabf4063 (2021).","journal-title":"Science"},{"key":"1614_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","volume":"584","author":"N Le Bert","year":"2020","unstructured":"Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 584, 457\u2013462 (2020).","journal-title":"Nature"},{"key":"1614_CR32","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2598-9","volume":"587","author":"J Braun","year":"2020","unstructured":"Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature 587, 270\u2013274 (2020).","journal-title":"Nature"},{"key":"1614_CR33","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1126\/science.abd3871","volume":"370","author":"J Mateus","year":"2020","unstructured":"Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science 370, 89\u201394 (2020).","journal-title":"Science"},{"key":"1614_CR34","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj6824","volume":"14","author":"C Riou","year":"2022","unstructured":"Riou, C. et al. Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Sci. Transl. Med. 14, eabj6824 (2022).","journal-title":"Sci. Transl. Med."},{"key":"1614_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"1614_CR36","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","volume":"44","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379\u20131391 (2016).","journal-title":"Immunity"},{"key":"1614_CR37","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41590-020-0782-6","volume":"21","author":"Y Peng","year":"2020","unstructured":"Peng, Y. et al. Broad and strong memory CD4. Nat. Immunol. 21, 1336\u20131345 (2020).","journal-title":"Nat. Immunol."},{"key":"1614_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168.e114 (2020).","journal-title":"Cell"},{"key":"1614_CR39","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"1614_CR40","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1128\/JVI.02392-06","volume":"81","author":"TC Friedrich","year":"2007","unstructured":"Friedrich, T. C. et al. Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 81, 3465\u20133476 (2007).","journal-title":"J. Virol."},{"key":"1614_CR41","doi-asserted-by":"publisher","first-page":"8677","DOI":"10.1128\/JVI.00869-15","volume":"89","author":"A Chowdhury","year":"2015","unstructured":"Chowdhury, A. et al. Differential impact of in vivo CD8+ T lymphocyte depletion in controller versus progressor simian immunodeficiency virus-infected macaques. J. Virol. 89, 8677\u20138686 (2015).","journal-title":"J. Virol."},{"key":"1614_CR42","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/nm.2447","volume":"17","author":"NJ Sullivan","year":"2011","unstructured":"Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128\u20131131 (2011).","journal-title":"Nat. Med."},{"key":"1614_CR43","doi-asserted-by":"publisher","first-page":"e149335","DOI":"10.1172\/JCI149335","volume":"131","author":"BA Woldemeskel","year":"2021","unstructured":"Woldemeskel, B. A., Garliss, C. C. & Blankson, J. N. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. J. Clin. Invest. 131, e149335 (2021).","journal-title":"J. Clin. Invest."},{"key":"1614_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24938-4","volume":"12","author":"J Bai","year":"2022","unstructured":"Bai, J. et al. Early CD4. Sci. Rep. 12, 20376 (2022).","journal-title":"Sci. Rep."},{"key":"1614_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-021-03841-4","volume":"597","author":"V Oberhardt","year":"2021","unstructured":"Oberhardt, V. et al. Rapid and stable mobilization of CD8. Nature 597, 268\u2013273 (2021).","journal-title":"Nature"},{"key":"1614_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32989-4","volume":"13","author":"N Kuse","year":"2022","unstructured":"Kuse, N. et al. Long-term memory CD8. Nat. Commun. 13, 5251 (2022).","journal-title":"Nat. Commun."},{"key":"1614_CR47","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1039\/C9TB01222B","volume":"7","author":"A Comberlato","year":"2019","unstructured":"Comberlato, A., Paloja, K. & Bastings, M. M. C. Nucleic acids presenting polymer nanomaterials as vaccine adjuvants. J. Mater. Chem. B 7, 6321\u20136346 (2019).","journal-title":"J. Mater. Chem. B"},{"key":"1614_CR48","doi-asserted-by":"publisher","first-page":"103699","DOI":"10.1016\/j.ebiom.2021.103699","volume":"74","author":"MN Vu","year":"2021","unstructured":"Vu, M. N., Kelly, H. G., Kent, S. J. & Wheatley, A. K. Current and future nanoparticle vaccines for COVID-19. EBioMedicine 74, 103699 (2021).","journal-title":"EBioMedicine"},{"key":"1614_CR49","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.3389\/fimmu.2018.02224","volume":"9","author":"R Pati","year":"2018","unstructured":"Pati, R., Shevtsov, M. & Sonawane, A. Nanoparticle vaccines against infectious diseases. Front. Immunol. 9, 2224 (2018).","journal-title":"Front. Immunol."},{"key":"1614_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.coviro.2021.03.008","volume":"48","author":"BZ Igy\u00e1rt\u00f3","year":"2021","unstructured":"Igy\u00e1rt\u00f3, B. Z., Jacobsen, S. & Ndeupen, S. Future considerations for the mRNA-lipid nanoparticle vaccine platform. Curr. Opin. Virol. 48, 65\u201372 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"1614_CR51","doi-asserted-by":"publisher","first-page":"20340","DOI":"10.1021\/acsnano.2c06275","volume":"16","author":"RR Du","year":"2022","unstructured":"Du, R. R. et al. Innate immune stimulation using 3D wireframe DNA origami. ACS Nano 16, 20340\u201320352 (2022).","journal-title":"ACS Nano"},{"key":"1614_CR52","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/s41565-024-01615-3","volume":"19","author":"YC Zeng","year":"2024","unstructured":"Zeng, Y. C. et al. Fine tuning of CpG spatial distribution with DNA origami for improved cancer vaccination. Nat. Nanotechnol. 19, 1055\u20131065 (2024).","journal-title":"Nat. Nanotechnol."},{"key":"1614_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41563-020-0793-6","volume":"20","author":"S Liu","year":"2021","unstructured":"Liu, S. et al. A DNA nanodevice-based vaccine for cancer immunotherapy. Nat. Mater. 20, 421\u2013430 (2021).","journal-title":"Nat. Mater."},{"key":"1614_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add1106","volume":"8","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. DNA origami\u2013based artificial antigen-presenting cells for adoptive T cell therapy. Sci. Adv. 8, eadd1106 (2022).","journal-title":"Sci. Adv."},{"key":"1614_CR55","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s42003-023-04689-2","volume":"6","author":"E Oktay","year":"2023","unstructured":"Oktay, E., Alem, F., Hernandez, K., Narayanan, A. & Veneziano, R. DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response. Commun. Biol. 6, 308 (2023).","journal-title":"Commun. Biol."},{"key":"1614_CR56","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","volume":"15","author":"R Veneziano","year":"2020","unstructured":"Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716\u2013723 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"1614_CR57","doi-asserted-by":"publisher","first-page":"21295","DOI":"10.1021\/jacs.2c09229","volume":"144","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Elucidating the effect of nanoscale receptor-binding domain organization on SARS-CoV-2 infection and immunity activation with DNA origami. J. Am. Chem. Soc. 144, 21295\u201321303 (2022).","journal-title":"J. Am. Chem. Soc."},{"key":"1614_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31684-8","volume":"13","author":"Y Sun","year":"2022","unstructured":"Sun, Y. et al. Nanoscale organization of two-dimensional multimeric pMHC reagents with DNA origami for CD8+ T cell detection. Nat. Commun. 13, 3916 (2022).","journal-title":"Nat. Commun."},{"key":"1614_CR59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0165-2427(98)00086-5","volume":"63","author":"G Karupiah","year":"1998","unstructured":"Karupiah, G. Type 1 and type 2 cytokines in antiviral defense. Vet. Immunol. Immunopathol. 63, 105\u2013109 (1998).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"1614_CR60","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cytogfr.2007.10.006","volume":"19","author":"P Fitzgerald-Bocarsly","year":"2008","unstructured":"Fitzgerald-Bocarsly, P., Dai, J. & Singh, S. Plasmacytoid dendritic cells and type I IFN: 50\u2009years of convergent history. Cytokine Growth Factor Rev. 19, 3\u201319 (2008).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1614_CR61","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"1614_CR62","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fimmu.2017.00194","volume":"8","author":"A Takeuchi","year":"2017","unstructured":"Takeuchi, A. & Saito, T. CD4 CTL, a cytotoxic subset of CD4. Front. Immunol. 8, 194 (2017).","journal-title":"Front. Immunol."},{"key":"1614_CR63","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103241","volume":"9","author":"G Goyal","year":"2022","unstructured":"Goyal, G. et al. Ectopic lymphoid follicle formation and human seasonal influenza vaccination responses recapitulated in an organ-on-a-chip. Adv. Sci. 9, e2103241 (2022).","journal-title":"Adv. Sci."},{"key":"1614_CR64","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.0105-2896.2005.00301.x","volume":"207","author":"KL Rock","year":"2005","unstructured":"Rock, K. L. & Shen, L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol. Rev. 207, 166\u2013183 (2005).","journal-title":"Immunol. Rev."},{"key":"1614_CR65","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(23)00352-3","volume":"23","author":"H Cohn","year":"2023","unstructured":"Cohn, H. et al. Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study. Lancet Infect. Dis. 23, 1302\u20131312 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"1614_CR66","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/erv.10.162","volume":"10","author":"C Cooper","year":"2011","unstructured":"Cooper, C. & Mackie, D. Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV\u2122 safety and efficacy. Expert Rev. Vaccines 10, 417\u2013427 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"1614_CR67","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41591-020-01145-0","volume":"27","author":"LE Wagar","year":"2021","unstructured":"Wagar, L. E. et al. Modeling human adaptive immune responses with tonsil organoids. Nat. Med. 27, 125\u2013135 (2021).","journal-title":"Nat. Med."},{"key":"1614_CR68","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR69","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/cid\/ciad718","volume":"78","author":"L Usdan","year":"2024","unstructured":"Usdan, L. et al. A bivalent Omicron-BA.4\/BA.5-adapted BNT162b2 booster in >\/=12-year-olds. Clin. Infect. Dis. 78, 1194\u20131203 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1614_CR70","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41551-020-00611-x","volume":"4","author":"M Norman","year":"2020","unstructured":"Norman, M. et al. Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nat. Biomed. Eng. 4, 1180\u20131187 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1614_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100208","volume":"10","author":"P Naaber","year":"2021","unstructured":"Naaber, P. et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg. Health Eur. 10, 100208 (2021).","journal-title":"Lancet Reg. Health Eur."},{"key":"1614_CR72","doi-asserted-by":"publisher","first-page":"2045857","DOI":"10.1080\/21645515.2022.2045857","volume":"18","author":"E Nanishi","year":"2022","unstructured":"Nanishi, E., Levy, O. & Ozonoff, A. Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review. Hum. Vaccin. Immunother. 18, 2045857 (2022).","journal-title":"Hum. Vaccin. Immunother."},{"key":"1614_CR73","doi-asserted-by":"publisher","first-page":"e2212073","DOI":"10.1001\/jamanetworkopen.2022.12073","volume":"5","author":"R Lassauniere","year":"2022","unstructured":"Lassauniere, R. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.1) 1 to 18\u2009weeks after the second and third doses of the BNT162b2 mRNA vaccine. JAMA Netw Open 5, e2212073 (2022).","journal-title":"JAMA Netw Open"},{"key":"1614_CR74","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm8451","volume":"16","author":"B Brook","year":"2024","unstructured":"Brook, B. et al. Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70. Sci. Transl. Med. 16, eadm8451 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1614_CR75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41591-024-03278-y","volume":"31","author":"DC Nguyen","year":"2025","unstructured":"Nguyen, D. C. et al. SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination. Nat. Med. 31, 235\u2013244 (2025).","journal-title":"Nat. Med."},{"key":"1614_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882856","volume":"13","author":"N Luan","year":"2022","unstructured":"Luan, N. et al. Th2-oriented immune serum after SARS-CoV-2 vaccination does not enhance infection. Front. Immunol. 13, 882856 (2022).","journal-title":"Front. Immunol."},{"key":"1614_CR77","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1056\/NEJMoa2024671","volume":"383","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544\u20131555 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR78","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","author":"D Laczk\u00f3","year":"2020","unstructured":"Laczk\u00f3, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53, 724\u2013732.e727 (2020).","journal-title":"Immunity"},{"key":"1614_CR79","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR80","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR81","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"1614_CR82","doi-asserted-by":"crossref","unstructured":"Young, O. J., et al. Cargo quantification of functionalized DNA origami for therapeutic application. Small Methods 9, e2401376 (2024).","DOI":"10.1002\/smtd.202401376"},{"key":"1614_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18910-x","volume":"11","author":"SFJ Wickham","year":"2020","unstructured":"Wickham, S. F. J. et al. Complex multicomponent patterns rendered on a 3D DNA-barrel pegboard. Nat. Commun. 11, 5768 (2020).","journal-title":"Nat. Commun."},{"key":"1614_CR84","doi-asserted-by":"publisher","first-page":"15903","DOI":"10.1021\/ja906381y","volume":"131","author":"Y Ke","year":"2009","unstructured":"Ke, Y. et al. Multilayer DNA origami packed on a square lattice. J. Am. Chem. Soc. 131, 15903\u201315908 (2009).","journal-title":"J. Am. Chem. Soc."},{"key":"1614_CR85","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.1073\/pnas.0700930104","volume":"104","author":"SM Douglas","year":"2007","unstructured":"Douglas, S. M., Chou, J. J. & Shih, W. M. DNA-nanotube-induced alignment of membrane proteins for NMR structure determination. Proc. Natl Acad. Sci. USA 104, 6644\u20136648 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1614_CR86","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/B978-0-12-420070-8.00008-8","volume":"536","author":"JS Nanda","year":"2014","unstructured":"Nanda, J. S. & Lorsch, J. R. Labeling a protein with fluorophores using NHS ester derivitization. Methods Enzymol. 536, 87\u201394 (2014).","journal-title":"Methods Enzymol."},{"key":"1614_CR87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15654","volume":"8","author":"N Ponnuswamy","year":"2017","unstructured":"Ponnuswamy, N. et al. Oligolysine-based coating protects DNA nanostructures from low-salt denaturation and nuclease degradation. Nat. Commun. 8, 1\u20139 (2017).","journal-title":"Nat. Commun."},{"key":"1614_CR88","doi-asserted-by":"publisher","first-page":"14216","DOI":"10.1073\/pnas.1111497108","volume":"108","author":"JR Whittle","year":"2011","unstructured":"Whittle, J. R. et al. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc. Natl Acad. Sci. USA 108, 14216\u201314221 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01614-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01614-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01614-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T10:01:42Z","timestamp":1773223302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-026-01614-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":88,"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1038\/s41551-026-01614-w","relation":{},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"29 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.M.S., J.H.R. and Y.C.Z. are inventors on US patent application PCT\/US2020\/036281 filed on 5 June 2020 by the Dana-Farber Cancer Institute, Korea Institute of Science & Technology and Wyss Institute, based on this work. Y.C.Z., W.M.S., J.H.R. and I.C.K. are the cofounders of a company called DoriNano, Inc., to translate the DoriVac technology. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}